When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps...
Original Article: Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy